MADISON, Wis.--(BUSINESS WIRE)-- In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified Service Provider (CSP) program. In July 2011, after passing their rigorous certification test plan, CCG received official certification as a Roche NimbleGen CSP for two microarray applications: array Comparative Genomic Hybridization (CGH) and gene expression.
"As a certified service provider, The Roy J. Carver Center for Genomics (CCG) will provide a full range of services for Roche NimbleGen applications including the recently certified array CGH and gene expression. The CCG is the first academic center in the US to attain this status, which emphasizes our expertise and commitment to provide high quality data to our investigators”, said Dr. Harsha Doddapaneni, Director of CCG. He further added, we have a dedicated climate controlled facility for processing all the critical array steps to ensure best quality results.
About this agreement, Dr. Bernd Fritzsch, DEO, Department of Biology of the CCG said, “The Roy J. Carver Center for Genomics is progressively exploring the opportunities inherent to the recent progress in genomic analysis. Becoming a certified service center for NimbleGen arrays is only the logical next step in this direction, guided by the leadership of Dr. H. Doddapaneni. Combined with the Developmental Studies Hybridoma Bank (DSHB), run expertly by Dr. David Soll, this is the second community outreach and service program provided by the Department of Biology to the Science Community. The collaboration with Roche NimbleGen is unique and signifies a strong liaison with a major force in genomics.”
“Roche NimbleGen is extremely excited to welcome the CCG as a Certified Service Provider for NimbleGen microarrays. This addition will provide more researchers with access to the innovative NimbleGen technologies, such as our ultra-high resolution 4.2M CGH arrays and high-throughput gene expression arrays. We look forward to this collaboration and the innovation and value it will provide to the research market” said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
About Roche (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY)
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
About the CCG: The Roy J. Carver Center for Genomics (CCG) is a research and service center within the Department of Biology on the campus of The University of Iowa. The CCG provides comprehensive service options for a number of genomic applications with strong emphasis on ‘NextGen’ sequencing and microarray applications. The CCG has a unique history of offering custom tailored project solutions for genomic applications and has expertise in handling projects with small starting quantity of RNA and DNA, whole cells and tissues. The CCG also offers services for construction of normalized cDNA, adapted to ‘NextGen’ sequencing for model as well as non-model species. For more information about the CCG, please visit www.biology.uiowa.edu/ccg/.
For life science research only. Not for use in diagnostic procedures.
454, 454 SEQUENCING and NIMBLEGEN are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
KEYWORDS: United States Europe North America Iowa Switzerland Wisconsin
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Genetics Medical Devices